Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results.

@article{Barkhof2007MagneticRI,
  title={Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results.},
  author={Frederik Barkhof and Chris H. Polman and Ernst-Wilhelm Radue and Ludwig Kappos and Mark Steven Freedman and Gilles Edan and H. P. Hartung and David H. Miller and Xavier Montalban and Peter A. Poppe and Marlieke de Vos and Fatiha Lasri and Lars Bauer and Susanne Dahms and Klaus Wagner and Christoph Pohl and Rupert Sandbrink},
  journal={Archives of neurology},
  year={2007},
  volume={64 9},
  pages={
          1292-8
        }
}
BACKGROUND In the Betaseron/Betaferon in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT) study, interferon beta-1b delayed conversion to multiple sclerosis in patients with a first clinical event and at least 2 clinically silent brain magnetic resonance imaging (MRI) lesions. OBJECTIVE To examine detailed MRI findings from the first 2 years of this trial. DESIGN Double-blind, placebo-controlled, randomized, parallel-group, multicenter, phase 3 study. SETTING Ninety-eight… 

Tables from this paper

Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes

TLDR
Both subcutaneous IFN β-1a 44 µg regimens improved MRI outcomes versus placebo, with the three times a week regimen having a more pronounced effect than once a week dosing.

Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study.

TLDR
The modified Barkhof criteria showed moderate predictive value for conversion to CDMS, although all patients had received interferon beta-1b therapy for at least 1 year, and the predictive value was unaffected by treatment intervention.

MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study

TLDR
MRI-measured disease activity was greatly reduced by both doses of cladribine tablets, with consistent effect across clinically relevant patient populations, and these findings add to the scientific understanding of the neurological impact of this therapeutic modality in patients with RRMS.

Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome

TLDR
Although the rate of lesions that converted to PBH showed no significant differences between groups, the numbers of PBHs per patient out of new lesions was significantly lower in IFNB-1b patients compared to patients on placebo.

Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis

TLDR
There is growing evidence from clinical trials on relapsing-remitting MS and clinically isolated syndromes suggestive of MS that IFNβ-1b reduces the frequency and severity of relapses and the development of new and active brain lesions as assessed by magnetic resonance imaging.

Interferon-β-1b

TLDR
Interferon-β-1b is a well established, first-line, disease-modifying therapy that has demonstrated efficacy in newly emerging MS, RRMS and SPMS with superimposed relapse in well designed clinical trials, and has a generally manageable tolerability profile, with no unexpected adverse events after many years of follow-up.

MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials

TLDR
Up-to-date recommendations for scan acquisition, image analysis, outcome-measure definition and standards of reporting are provided and safety considerations in the use of MRI in MS trials are addressed.

Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study

TLDR
Over 5 years in patients presenting with an FCDE, early sc IFN β-1a tiw administration versus DT prolonged time to CDMS and McDonald MS, and reduced overall MRI activity.

Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials

  • D. Bates
  • Psychology, Medicine
    Neurology
  • 2011
TLDR
Current evidence suggests that IFNβ therapy may be more effective in the early stages of SPMS, characterized by relapsing episodes and MRI evidence of greater brain lesion disease activity, and intervention with IFN β therapy is appropriate for all stages of MS except PPMS or non-relapsing SPMS.

Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.

TLDR
The primary outcomes were disability-worsening, relapses, occurrence of at least one serious adverse event (AE) and withdrawing from the study or discontinuing the drug because of AEs and the credibility of the evidence was evaluated using the GRADE system.
...

References

SHOWING 1-10 OF 25 REFERENCES

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.

TLDR
Starting treatment with interferon beta-1a at the time of a first demyelinating event is beneficial for patients with brain lesions on MRI that indicate a high risk of clinically definite multiple sclerosis.

Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

TLDR
The MRI results demonstrate that IFNB has made a significant impact on the natural history of MS in these patients and support the clinical results in showing a significant reduction in disease activity as measured by numbers of active scans and appearance of new lesions.

Effect of interferon‐β1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a European multicenter, randomized, double‐blind, placebo‐controlled trial

TLDR
Interferon‐β1b has a substantial and sustained effect on reducing the accumulation of new inflammatory disease foci in secondary progressive MS and this therapeutic mechanism may contribute to the positive clinical benefits of treatment on the progression of sustained neurological disability and relapse activity.

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

TLDR
Interferon beta-1b 250 μg subcutaneously every other day delayed conversion to clinically definite multiple sclerosis, and should be considered as a therapeutic option in patients presenting with a first clinical event suggestive of multiple sclerosis.

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

TLDR
Interferon beta-1b 250 μg subcutaneously every other day delayed conversion to clinically definite multiple sclerosis, and should be considered as a therapeutic option in patients presenting with a first clinical event suggestive of multiple sclerosis.

T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment.

TLDR
In patients with SP multiple sclerosis, IFNbeta-1b treatment reduces the development of hypointense T(1) lesions, suggesting that reduced axonal damage in lesions may play a part in the beneficial effect that is observed clinically.

Using gadolinium‐enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis

TLDR
Monitoring Gd‐enhancing lesions may be an effective tool to assist in the assessment of experimental therapies in early MS, and a crossover design with study arms of sufficient duration was used to allow accurate estimation of lesion frequency.

Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis

TLDR
MRI enabled us to demonstrate that the duration of the effect of methylprednisolone treatment is temporary, and no beneficial effect was observed on the rate of disappearance of related abnormalities on T2-weighted images, indicating persistent change such as oedema, cellular infiltration or demyelination.